Mark Anthony McCamish - 04 Feb 2026 Form 4 Insider Report for AVADEL PHARMACEUTICALS PLC (AVDL)

Role
Director
Signature
/s/ Jerad G. Seurer, as Attorney-in-Fact
Issuer symbol
AVDL
Transactions as of
04 Feb 2026
Net transactions value
$0
Form type
4
Filing time
06 Feb 2026, 16:10:10 UTC
Previous filing
31 Jul 2025
Next filing
12 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
McCamish Mark Anthony Director C/O AVADEL PHARMACEUTICALS PLC, 10 EARLSFORT TERRACE, DUBLIN 2, IRELAND /s/ Jerad G. Seurer, as Attorney-in-Fact 06 Feb 2026 0001390798

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVDL Ordinary Shares Gift $0 -67,025 -100% $0.000000 0 04 Feb 2026 By Matthew 5 LLC F1, F2
transaction AVDL Ordinary Shares Gift $0 +67,025 $0.000000 67,025 04 Feb 2026 By McCamish Charitable Remainder Trust F1, F3
holding AVDL Ordinary Shares 22,000 04 Feb 2026 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On February 4, 2026, the Reporting Person transferred 67,025 shares from Matthew 5 LLC to the McCamish Charitable Remainder Trust.
F2 Shares held by Matthew 5 LLC. The Mark & Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and the Reporting Person serves as its manager.
F3 Shares held by McCamish Charitable Remainder Trust, of which the Reporting Person and his spouse are income beneficiaries. The Reporting Person disclaims beneficial ownership except to the extent of his and his spouse's pecuniary interest therein.